Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Positive preclinical results for third BL-8040 indication
March 2014
SHARING OPTIONS:

JERUSALEM—Biopharmaceutical company BioLineRx has released positive preclinical results for BL-8040 as a treatment for chronic myeloid leukemia (CML), which marks the third indication for the drug; BL-8040 is also in clinical development for acute myeloid leukemia, and is expected to begin a Phase 1 trial in stem cell mobilization in the second quarter of this year. BL- 8040’s effectiveness was studied both as a monotherapy and in combination with imatinib, and results showed that the drug candidate directly inhibited cancer cell growth and induced apoptosis of CML cells in vitro. It also demonstrated a synergistic effect with imatinib, as the combination inhibited tumor growth by 95 percent in mice engrafted with CML tumors and also reversed the shielding effect of the bone marrow stroma on CML cells, encouraging apoptosis.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.